



ASX ANNOUNCEMENT

Lumos Secures Feasibility Project with Burnet Diagnostics Initiative

MELBOURNE, Australia (27 July 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce it has signed a commercial contract to undertake an initial feasibility project with the Burnet Diagnostics Initiative (BDI) of the Macfarlane Burnet Institute for Medical Research and Public Health Ltd.

The project will build upon preliminary proof-of-concept work conducted by BDI on a novel companion diagnostic biomarker with utility across a range of human health applications. Lumos will conduct feasibility level development studies to generate a prototype test for evaluation with clinical specimens. This initial feasibility stage of the project is worth up to US\$200,000 in revenue for Lumos and is expected to complete within approximately four months. If successful, Lumos may be engaged to assist with subsequent stages of the project including product design, development and manufacturing.

“We are very excited to be able to access Lumos’ expertise to accelerate our development activities for this project,” said Jennifer Barnes, CEO of the Burnet Diagnostics Initiative. “We selected Lumos for their ability to develop new diagnostic products from the initial assay feasibility through to a commercial product, ensuring compliance to ISO 13485 medical device standard. Access to their reader platform, which provide the ability to access results remotely was an important factor in our decision to proceed with Lumos.”

“We have been very impressed with work that BDI is doing in developing new, rapid POC diagnostic products for human health applications,” said Doug Ward, CEO Lumos. “Over the past 15 years, they have had great success with developing a number of important products and have a pipeline of exciting projects underway. We are honoured to be able to provide our experience and expertise to assist them in this latest project and are greatly looking forward to working with them going forward”.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About Burnet Diagnostics Institute

The Burnet Diagnostics Initiative (BDI) is a commitment by the Burnet Institute to develop the systems, resources and processes to support diagnostic product development and enhance translation of its point-of-care diagnostics research into practical health solutions. The BDI is building capacity in Melbourne for its internal research and for engagement with the In Vitro Diagnostics (IVD) industry through strategic partnerships

For more information visit burnet.edu.au.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598